How can we help?
SCL-70 Antibody, Serum

SCL-70 Antibody, Serum

Also referred as
Scleroderma Antibody (Scl-70)
For men & women
Earliest reports in
120-144 hours
Contains
1 test
Know more about this test

The SCL-70 Antibody, Serum test detects antibodies against topoisomerase I (SCL-70) in the blood. This test supports evaluation and differentiation of systemic sclerosis (scleroderma) from other connective tissue disorders.

Samples required
Blood
Find out
Why is this test booked?
Preparation for this test
Sample Collection
Who will collect your samples?

Understanding SCL-70 Antibody, Serum

SCL-70, also known as DNA topoisomerase I, is an enzyme found in the cell nucleus that helps unwind DNA during replication and transcription. In certain autoimmune conditions, the immune system mistakenly produces antibodies against this enzyme. The presence of SCL-70 antibodies in the blood suggests abnormal immune activity and is considered a significant marker for systemic sclerosis (scleroderma).

SCL-70 antibodies are strongly associated with diffuse cutaneous systemic sclerosis, a severe form of scleroderma that can affect the skin, lungs, kidneys, and other internal organs.  However, these antibodies are not exclusive and may appear in overlap syndromes. 

This test supports the diagnosis when combined with clinical findings and other tests and assesses the risk of complications, especially interstitial lung disease. These antibodies may also appear in other autoimmune diseases like lupus or mixed connective tissue disease (MCTD), but with lower specificity.

Doctors may recommend the SCL-70 Antibody, Serum test if there are symptoms such as thickened or hardened skin, joint stiffness, Raynaud’s phenomenon, shortness of breath, or unexplained fatigue, which may suggest systemic sclerosis. Often performed alongside other antibody panels (such as ANA or ENA profiles), this test plays an important role in early detection, accurate disease classification, and guiding long-term treatment. By identifying these antibodies, doctors can monitor disease progression, anticipate potential organ involvement, and plan appropriate therapies.

Usually, no special preparation is required for this test. Eat and drink as per the daily routine. However, sharing the clinical history, current medications, and supplement use with the doctor before giving the sample is preferred, as these may influence the results.

Test result ranges are approximate and may differ slightly between labs depending on the methodology and laboratory guidelines. Do not self-medicate and always consult a doctor to understand the test results correctly. 

Please note: This is an outsourced test. The sample for this test is collected by TATA 1MG and processed at a NABL accredited partnered lab.

See more

What does SCL-70 Antibody, Serum measure?

The SCL-70 Antibody, Serum test detects anti-topoisomerase I antibodies in the blood. These autoantibodies target topoisomerase I, an enzyme essential for unwinding DNA during cell replication. Their presence indicates an autoimmune reaction, where the immune system mistakenly attacks the body’s own tissues.

SCL-70 antibodies are found in about 40% of patients with progressive systemic sclerosis (PSS). A positive result suggests a higher likelihood of systemic sclerosis, particularly the diffuse cutaneous type, which is more often associated with lung and internal organ involvement. However, not all patients with systemic sclerosis test positive for SCL-70 antibodies, and in some cases, these antibodies may also appear in other connective tissue diseases. A negative result does not rule out systemic sclerosis but makes the diagnosis less likely. Results must always be interpreted in combination with symptoms, physical findings, and other laboratory and imaging studies, not standalone. 

FAQs related to SCL-70 Antibody, Serum

The SCL-70 Antibody, Serum test is a blood test that supports systemic sclerosis evaluation by finding out antibodies against topoisomerase I, a nuclear enzyme and risk assessment, and disease monitoring.
Your doctor may order this test if you have symptoms such as skin thickening, joint stiffness, Raynaud’s phenomenon, difficulty breathing, or fatigue, which may suggest systemic sclerosis or another autoimmune connective tissue disease.
No, fasting is not required for the SCL-70 Antibody, Serum test.
A positive result strongly suggests systemic sclerosis, especially the diffuse form, which carries a higher risk of lung and kidney complications. It may occasionally appear in other autoimmune diseases like lupus or mixed connective tissue disease. Results should be correlated clinically.
A negative result means that SCL-70 antibodies were not detected. However, this does not completely rule out systemic sclerosis or other autoimmune conditions. Your doctor may suggest additional tests like anti-centromere or anti-RNP antibodies, depending on your symptoms.
Yes. The SCL-70 Antibody, Serum test is often ordered with ANA (antinuclear antibody) and ENA (extractable nuclear antigen) panels to provide a clearer picture of autoimmune activity and to differentiate between overlapping connective tissue disorders.
Rarely, these antibodies may also appear in other autoimmune connective tissue disorders, but they are most specific for systemic sclerosis.
Tata 1mg ensures accurate lab test results through certified laboratories that use advanced technology and adhere to stringent quality control measures. This commitment to high standards guarantees reliable results.

SCL-70 Antibody, Serum test price for other cities

Price inNew DelhiRs. 1379
Price inKolkataRs. 1169
Price inPuneRs. 1699
Price inBangaloreRs. 1589
Price inChandigarhRs. 1150

How does home sample collection work?

Download the Tata 1mg app. Trusted healthcare, at your fingertips.

Book tests, track reports, and get AI-powered health insights.

or
Conducted by
NABL accredited partner lab
Accredited labs
Highly skilled Phlebos
Verified reports
Who will collect your samples?
Tata 1mg certified phlebotomists
Contains 1 test
SCL-70 Antibody, Serum